Behavior problems and psychotropic drug use in children and adolescents with mental retardation.

H. Tobi, A. de Bildt, E.J. Mulder, T. Scheers, R.B. Minderaa

Research output: Contribution to journalMeeting AbstractAcademic

Abstract

Background: Children with mental retardation (MR) are a vulnerable not much studied population. Objectives: To investigate psychopharmacotherapy in children with MR and to examine possible factors associated with psychopharmacotherapy. Methods: Participants were recruited through all facilities for children with mental retardation in Friesland, the Netherlands, resulting in 865 participants, 4–18 years old, including all levels of mental retardation. The DBC and the PDD-MRS were used to assess general behavior problems and Pervasive Developmental Disorders (PDD). Information on medication was collected through a parent-interview. Logistic regression was used to investigate the relationship between the psychotropic drug use and the factors DBC, PDD, housing, age, gender and level of MR. Results: 10% of the participants used psychotropic medication. Main factors associated with receiving psychopharmacotherapy were PDD (OR 2.31) and DBC score (OR 1.03). Living away from home and MR-level also played a role whereas gender and age did not. DBC score was associated with clonidine, stimulants and anti-psychotics. PDD was the main factor associated with anti-psychotics use (OR 5.7). Discussion: Psychopharmacotherapy is especially prevalent among children with MR and comorbid PDD and general behavior problems. Although many psychotropic drugs are used off-label, specific drugs were associated with specific psychiatric or behavior problems.
Original languageEnglish
Pages (from-to)151-151
JournalEuropean Journal of Epidemiology
Volume21
Issue numberSuppl.1
Publication statusPublished - 2006

Fingerprint

Psychotropic Drugs
Intellectual Disability
Clonidine
Problem Behavior
Netherlands
Psychiatry
Logistic Models
Interviews
Pharmaceutical Preparations
Population

Cite this

Tobi, H., de Bildt, A., Mulder, E. J., Scheers, T., & Minderaa, R. B. (2006). Behavior problems and psychotropic drug use in children and adolescents with mental retardation. European Journal of Epidemiology, 21(Suppl.1), 151-151.
Tobi, H. ; de Bildt, A. ; Mulder, E.J. ; Scheers, T. ; Minderaa, R.B. / Behavior problems and psychotropic drug use in children and adolescents with mental retardation. In: European Journal of Epidemiology. 2006 ; Vol. 21, No. Suppl.1. pp. 151-151.
@article{3ae6fe2c8ec3474292204699163168fa,
title = "Behavior problems and psychotropic drug use in children and adolescents with mental retardation.",
abstract = "Background: Children with mental retardation (MR) are a vulnerable not much studied population. Objectives: To investigate psychopharmacotherapy in children with MR and to examine possible factors associated with psychopharmacotherapy. Methods: Participants were recruited through all facilities for children with mental retardation in Friesland, the Netherlands, resulting in 865 participants, 4–18 years old, including all levels of mental retardation. The DBC and the PDD-MRS were used to assess general behavior problems and Pervasive Developmental Disorders (PDD). Information on medication was collected through a parent-interview. Logistic regression was used to investigate the relationship between the psychotropic drug use and the factors DBC, PDD, housing, age, gender and level of MR. Results: 10{\%} of the participants used psychotropic medication. Main factors associated with receiving psychopharmacotherapy were PDD (OR 2.31) and DBC score (OR 1.03). Living away from home and MR-level also played a role whereas gender and age did not. DBC score was associated with clonidine, stimulants and anti-psychotics. PDD was the main factor associated with anti-psychotics use (OR 5.7). Discussion: Psychopharmacotherapy is especially prevalent among children with MR and comorbid PDD and general behavior problems. Although many psychotropic drugs are used off-label, specific drugs were associated with specific psychiatric or behavior problems.",
author = "H. Tobi and {de Bildt}, A. and E.J. Mulder and T. Scheers and R.B. Minderaa",
year = "2006",
language = "English",
volume = "21",
pages = "151--151",
journal = "European Journal of Epidemiology",
issn = "0393-2990",
publisher = "Springer Verlag",
number = "Suppl.1",

}

Tobi, H, de Bildt, A, Mulder, EJ, Scheers, T & Minderaa, RB 2006, 'Behavior problems and psychotropic drug use in children and adolescents with mental retardation.' European Journal of Epidemiology, vol. 21, no. Suppl.1, pp. 151-151.

Behavior problems and psychotropic drug use in children and adolescents with mental retardation. / Tobi, H.; de Bildt, A.; Mulder, E.J.; Scheers, T.; Minderaa, R.B.

In: European Journal of Epidemiology, Vol. 21, No. Suppl.1, 2006, p. 151-151.

Research output: Contribution to journalMeeting AbstractAcademic

TY - JOUR

T1 - Behavior problems and psychotropic drug use in children and adolescents with mental retardation.

AU - Tobi, H.

AU - de Bildt, A.

AU - Mulder, E.J.

AU - Scheers, T.

AU - Minderaa, R.B.

PY - 2006

Y1 - 2006

N2 - Background: Children with mental retardation (MR) are a vulnerable not much studied population. Objectives: To investigate psychopharmacotherapy in children with MR and to examine possible factors associated with psychopharmacotherapy. Methods: Participants were recruited through all facilities for children with mental retardation in Friesland, the Netherlands, resulting in 865 participants, 4–18 years old, including all levels of mental retardation. The DBC and the PDD-MRS were used to assess general behavior problems and Pervasive Developmental Disorders (PDD). Information on medication was collected through a parent-interview. Logistic regression was used to investigate the relationship between the psychotropic drug use and the factors DBC, PDD, housing, age, gender and level of MR. Results: 10% of the participants used psychotropic medication. Main factors associated with receiving psychopharmacotherapy were PDD (OR 2.31) and DBC score (OR 1.03). Living away from home and MR-level also played a role whereas gender and age did not. DBC score was associated with clonidine, stimulants and anti-psychotics. PDD was the main factor associated with anti-psychotics use (OR 5.7). Discussion: Psychopharmacotherapy is especially prevalent among children with MR and comorbid PDD and general behavior problems. Although many psychotropic drugs are used off-label, specific drugs were associated with specific psychiatric or behavior problems.

AB - Background: Children with mental retardation (MR) are a vulnerable not much studied population. Objectives: To investigate psychopharmacotherapy in children with MR and to examine possible factors associated with psychopharmacotherapy. Methods: Participants were recruited through all facilities for children with mental retardation in Friesland, the Netherlands, resulting in 865 participants, 4–18 years old, including all levels of mental retardation. The DBC and the PDD-MRS were used to assess general behavior problems and Pervasive Developmental Disorders (PDD). Information on medication was collected through a parent-interview. Logistic regression was used to investigate the relationship between the psychotropic drug use and the factors DBC, PDD, housing, age, gender and level of MR. Results: 10% of the participants used psychotropic medication. Main factors associated with receiving psychopharmacotherapy were PDD (OR 2.31) and DBC score (OR 1.03). Living away from home and MR-level also played a role whereas gender and age did not. DBC score was associated with clonidine, stimulants and anti-psychotics. PDD was the main factor associated with anti-psychotics use (OR 5.7). Discussion: Psychopharmacotherapy is especially prevalent among children with MR and comorbid PDD and general behavior problems. Although many psychotropic drugs are used off-label, specific drugs were associated with specific psychiatric or behavior problems.

M3 - Meeting Abstract

VL - 21

SP - 151

EP - 151

JO - European Journal of Epidemiology

JF - European Journal of Epidemiology

SN - 0393-2990

IS - Suppl.1

ER -